Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of
N6022, and to obtain descriptive information on the effect of N6022 on biomarkers of CFTR
function and inflammation in adult cystic fibrosis subjects who are homozygous for the
F508del-CFTR mutation.